69 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... First Episode of Opportunistic ... #Prophylaxis #Opportunistic ... #OIs #HIVAIDS #IDSA ... #management #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... First Episode of Opportunistic ... #Prophylaxis #Opportunistic ... #OIs #HIVAIDS #IDSA ... #management #pharmacology
Parenteral Antimicrobial Treatment of Common Microorganisms Causing Native Vertebral Osteomyelitis - IDSA 
Staphylococci, oxacillin susceptible
Staphylococci, oxacillin
Osteomyelitis - IDSA ... #Parenteral #IV ... Osteomyelitis #management ... #pharmacology #idsa
Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19

IL-6 activates T cells and macrophages, among other cell types (see
Siltuximab) in COVID19 ... Cytokine Activation Syndrome ... suggested dose 400mg) IV ... Siltuximab 11mg/kg IV ... #Pharmacology #Management
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
IDSA Recommendations ... PO (or 400 mg IV ... Enteric #Bacterial #IDSA ... Prevention #Treatment #management ... #opportunistic
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
IDSA Recommendations ... to 5 mg/kg/day IV ... Penicilliosis #IDSA ... Prevention #Treatment #management ... #opportunistic
QTc Flow chart to minimize TdP in COVID-19 inpatients on Chloroquine/Azithromycin

Flow chart to manage effects on
minimize TdP in COVID ... LQTS: long QT syndrome ... beats per minute; IV ... dobutamine #COVID19 ... Torsades #Algorithm #Management
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
IDSA Recommendations ... amphotericin B 2–4 mg/kg IV ... amphotericin B 2–4 mg/kg IV ... Prevention #Treatment #management ... #opportunistic
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... 400 mg) PO or IV ... candida #mucosal #IDSA ... Prevention #Treatment #management ... #opportunistic
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
IDSA Recommendations ... Infection General Management ... IsosporaBelli #IDSA ... Prevention #Treatment #management ... #opportunistic